Al-Gawahiri Malak, Barenbrug Liana, Bronkhorst Ewald M, de Jong Elke M G J, van den Reek Juul M P A, Seyger Marieke M B
Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of IQ Health, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
J Dermatolog Treat. 2025 Dec;36(1):2532672. doi: 10.1080/09546634.2025.2532672. Epub 2025 Jul 23.
Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study.
Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children's) Dermatology Life Quality Index ((C)DLQI) scores between sexes.
We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males.
Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.
成年银屑病患者生物治疗效果的性别差异已为人熟知。本研究调查了在现实世界中使用生物制剂的儿童及青年银屑病患者队列中的潜在性别差异。
从前瞻性日常实践的儿童CAPTURE和生物CAPTURE登记处获取儿童（<18岁）和青年（≥18至≤30岁）患者的数据。比较了不同性别的药物生存率和不良事件发生率。使用经混杂因素校正的线性混合模型比较不同性别之间的银屑病面积和严重程度指数（PASI）以及（儿童）皮肤病生活质量指数（(C)DLQI）得分。
我们纳入了117例接受生物制剂治疗的儿童患者（65例女性）和243例青年患者（124例女性）（共753.4观察年）。青年男性在开始使用生物制剂时的PASI显著高于女性，儿童患者也有相同趋势。在儿童和青年患者中，女性的不良事件发生率均高于男性。儿童和青年女性及男性在首个治疗年期间的药物生存率、PASI和(C)DLQI病程相当。
了解儿童及青年银屑病患者的性别差异（起始PASI和不良事件发生率）对于及时启动和调整适当治疗很重要。
